Physical Hazard

In insurance, a physical hazard is any tangible characteristic of property, people, or activities that increases the probability of loss due to a peril. These hazards are related to the physical condition of the property or people and can contribute to the likelihood and severity of a loss.

Examples of physical hazards include:

• Faulty wiring that increases the likelihood of a fire

• Slippery floors that increase the likelihood of a slip and fall accident

• Defective machinery that increases the likelihood of an accident or injury

• Proximity to flood-prone areas that increases the likelihood of flood damage

Key features of physical hazards in insurance include:

• They are tangible characteristics that are visible or measurable.

• They increase the likelihood of loss due to a peril.

• They can affect the severity of a loss.

• They can be mitigated or eliminated through risk management techniques such as repairs, maintenance, or protective measures.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.